uniQure (XTRA:UQ1) - Cotización, noticias y análisis

Resumen de acción UQ1

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.

UQ1 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 87% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 42.81%

Análisis de riesgos

Acciones altamente ilíquidas

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de uniQure N.V.

Formycon

XTRA:FYB

€674.6m

Biotest

XTRA:BIO3

€1.4b

MorphoSys

XTRA:MOR

€2.6b

Heidelberg Pharma

XTRA:HPHA

€139.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for uniQure
Historical stock prices
Current Share Price	US$18.64
52 Week High	US$31.11
52 Week Low	US$12.29
Beta	0.95
1 Month Change	0%
3 Month Change	-4.44%
1 Year Change	-40.10%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-40.77%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	UQ1	DE Biotechs	Mercado DE
7D	0%	-5.1%	-2.0%
1Y	-40.1%	-21.1%	-0.3%

Rentabilidad vs. Industria: UQ1 obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -23.4%.

Rentabilidad vs. Mercado: UQ1 obtuvo unos resultados inferiores a los del mercado German, que fue del 4.7% el año pasado.

Volatilidad de los precios

Is UQ1's price volatile compared to industry and market?
UQ1 volatility
UQ1 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: UQ1ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de UQ1 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1998	463	Matt Kapusta	www.uniqure.com

Resumen de fundamentos de uniQure N.V.

¿Cómo se comparan los beneficios e ingresos de uniQure con su capitalización de mercado?
Estadísticas fundamentales de UQ1
Capitalización bursátil	€899.25m
Beneficios(TTM)	-€125.41m
Ingresos (TTM)	€61.44m

14.6x

Ratio precio-ventas (PS)

-7.2x

Ratio precio-beneficio (PE)

¿Está UQ1 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de UQ1
Ingresos	US$61.43m
Coste de los ingresos	US$125.95m
Beneficio bruto	-US$64.52m
Otros gastos	US$60.87m
Beneficios	-US$125.39m

Últimos beneficios comunicados

Sep 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.68
Margen bruto	-105.03%
Margen de beneficio neto	-204.12%
Ratio deuda/patrimonio	24.3%

¿Cómo se ha desempeñado UQ1 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción UQ1

Recompensas

Análisis de riesgos

Competidores de uniQure N.V.

XTRA:FYB

€674.6m

XTRA:BIO3

€1.4b

XTRA:MOR

€2.6b

XTRA:HPHA

€139.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

uniQure N.V. Announces Executive Changes

Recent updates

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

uniQure N.V. Announces Executive Changes

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Second quarter 2022 earnings released: US$0.84 loss per share (vs US$8.68 profit in 2Q 2021)

Investor sentiment improved over the past week

uniQure N.V. Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Investor sentiment improved over the past week

Chief Operating Officer recently sold €95k worth of stock

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

First quarter 2022 earnings released: US$1.00 loss per share (vs US$0.91 loss in 1Q 2021)

uniQure N.V., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

CEO & Executive Director recently sold €152k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

CEO & Executive Director recently sold €175k worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.79 loss per share (vs US$1.21 loss in 3Q 2020)

President of Research & Development recently sold €271k worth of stock

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$8.68 (vs US$0.96 loss in 2Q 2020)

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure N.V. Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

No longer forecast to breakeven

uniQure N.V. Presents Hope-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Antibodies to Aav5 Vector

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.63 loss in 1Q 2020)

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

CEO, CFO & Executive Director recently sold €152k worth of stock

Full year 2020 earnings released: US$2.81 loss per share (vs US$3.11 loss in FY 2019)

Revenue misses expectations

uniQure N.V. Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Chief Accounting Officer recently sold €261k worth of stock

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de uniQure N.V.

14.6x

-7.2x

Beneficios e Ingresos